Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Fella M. 'Hammedi-Bouzina"'
Autor:
Simona Lapusan, Elise Corre, Zoé Van de Wyngaert, Annalisa Paviglianiti, Fella M. ’Hammedi-Bouzina, Eolia Brissot, Zora Marjanovic, Florent Malard, Myriam Labopin, Ollivier Legrand, Anne Banet, Rosa Adaeva, Mohamad Mohty, Alexis Genthon, Remy Dulery, Souhila Ikhlef, Simona Sestilli
Publikováno v:
Bone Marrow Transplantation
Autor:
Patrick Ingiliz, Karine Lacombe, Simona Lapusan, Alexis Genthon, Arsène Mekinian, Fella M. ’Hammedi-Bouzina, Eolia Brissot, Pierre Baylac, Jérôme Pacanowski, Nadia Valin, Tomas Urbina, Mohamad Mohty, T. Chiarabini
Publikováno v:
Leukemia & Lymphoma
Leukemia & lymphoma
Leukemia & lymphoma, Taylor & Francis, 2021, 62 (6), pp.1502-1505. ⟨10.1080/10428194.2020.1869963⟩
Leukemia & lymphoma, 2021, 62 (6), pp.1502-1505. ⟨10.1080/10428194.2020.1869963⟩
Leukemia & lymphoma
Leukemia & lymphoma, Taylor & Francis, 2021, 62 (6), pp.1502-1505. ⟨10.1080/10428194.2020.1869963⟩
Leukemia & lymphoma, 2021, 62 (6), pp.1502-1505. ⟨10.1080/10428194.2020.1869963⟩
The course of the COVID-19 infection has been better understood since the first identification of a novel beta-coronavirus (SARS-CoV-2) in early January 2020 in Wuhan, China [1]. Some individuals w...
Autor:
Rosa Adaeva, Souhila Ikhlef, Simona Lapusan, Annalisa Paviglianiti, Simona Sestili, Mohamad Mohty, Remy Dulery, Alexis Genthon, Fella M. ’Hammedi-Bouzina, Eolia Brissot, Ollivier Legrand, Myriam Labopin, Agnès Bonnin, Florent Malard, Elise Corre, Zoé Van de Wyngaert, Zora Marjanovic, Anne Banet
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, 2020, 20, pp.791-796. ⟨10.1016/j.clml.2020.07.001⟩
Clinical Lymphoma, Myeloma & Leukemia, 2020, 20, pp.791-796. ⟨10.1016/j.clml.2020.07.001⟩
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, 2020, 20, pp.791-796. ⟨10.1016/j.clml.2020.07.001⟩
Clinical Lymphoma, Myeloma & Leukemia, 2020, 20, pp.791-796. ⟨10.1016/j.clml.2020.07.001⟩
Background More than one-third of patients with acute myeloid leukemia (AML) will relapse after allogenic hematopoietic cell transplant (allo-HCT). The main challenge is to overcome disease resistance to achieve a new complete remission while avoidin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e248989048c46f995c0dc0888810e80
https://hal.archives-ouvertes.fr/hal-03492848
https://hal.archives-ouvertes.fr/hal-03492848